The recombinant vaccine has become a new step in medicine and vaccination. Currently, this type of vaccination is most widely used, effectively preventing hepatitis B. Let's consider the general features of drugs of this class, their key differences. Let's pay attention to the most famous products.
General information
Production of a recombinant vaccine involves first cloning the genetic material to generate an antigen, then introducing the resulting raw material into a vector, introducing the vector into producers. The next step is laboratory cultivation, after which the antigen is isolated and purified. An alternative option is to use producers as an element of the vaccine.
The prepared product must first be studied. To do this, a reference drug is used that has successfully passed tests at the preclinical level and at the clinical stage. Differences between different series indicate unstable vectors and the loss of such vectors by the cellular material in the course of work. At the final stage of the work, it is necessary to check how large the percentage of cells including the vector is. To the virus vectorformulate stringent requirements. Attenuation should be high, while oncogenic activity is unacceptable. It is unacceptable to use material that provokes additional unwanted effects.
Drugs of the future?
Recombinant vaccines are completely safe, scientists say. Such funds show a high degree of effectiveness. The production process of such a pharmaceutical product involves the use of the most effective and modern methods and technologies. Finished products are used to create complex preparations for vaccination of the population. Their use allows people to develop immunity against several pathogens at the same time.
About famous products: "Bubo-Kok"
The vaccine "Bubo-Kok" is produced in the form of a suspension intended for injection into muscle tissues. The remedy is not used with increased susceptibility by the body, progressive nervous pathologies, severe complications that previously appeared on the background of vaccination. Do not use the drug if the patient has previously suffered afebrile convulsions. The vaccine is not administered in the acute phase of the disease, during the period of recurrence of chronic pathology. In such conditions, vaccination is postponed until the person in need has recovered.
The Bubo-Kok vaccine is injected into a muscle, into the buttock. An outer quadrant must be used. It is allowed to enter into the anterior lateral femoral surface. A single dosage is half a milliliter. The vaccine is given based on the national vaccination schedule. If the child is under three months oldage has not received the hepatitis B vaccine, it is necessary to inject "Bubo-Kok" three times. Initially, the injection is given at the age of three months, then repeated twice with one and a half month pauses.
Application features
If the use of the Bubo-Kok recombinant vaccine is required, it is strictly forbidden to shorten the pauses between injections. Sometimes there is a need to increase the waiting periods. In this case, the drug is administered immediately, as soon as children's he alth allows injection. If DTP injections were previously administered once or twice, and no hepatitis B preventive was obtained, an additional administration of a monovaccine should be made. They use Bubo-Kok medicine to complete the vaccination course, which should include receiving prophylactic drugs three times.
Re-vaccination is carried out by the introduction of DTP once at 18 months of age. If the standard terms are violated, a second injection is prescribed 12-13 months after the first course. If a booster vaccine has not yet been received by the age of four years, toxoid ADS for children under six years of age or ADS-M for older individuals is used for administration.
Activity Features
If you ask a doctor what “recombinant vaccine” means, how it works, the doctor will answer that it is a specially manufactured pharmaceutical product designed to prevent serious illnesses. The manufacturing process is described above. The pharmacology of the drug is such that a person has a specific immunity that preventstetanus disease, excluding whooping cough, diphtheria and hepatitis B.
The use of such a drug comes with certain risks. Recombinant vaccination can cause short-term systemic, local reactions. The temperature may rise, the general condition of the child is weak, the injection area responds with pain and is hot to the touch. There is a possibility of local edema. Usually this appears in the first two days after the introduction. Rarely, the injection results in seizures, allergies, and screaming episodes.
Recombinant Yeast Vaccine
This product is manufactured by the domestic pharmaceutical company Combiotech. It has the chemical formula of an aluminum-sorbed protein produced by a recombinant yeast strain. The composition contains antigen determinants, which provides protection against hepatitis B. The vaccine includes 20 micrograms of protein, half a milligram of an aluminum compound. It is possible to include a preservative ingredient - merthiolate. If there is one, it is used in the amount of 50 mcg. You can check the presence of a preservative in the instructions that accompany a specific release.
The vaccine is designed to be injected into muscle tissue. You can not use the drug in the acute course of the disease, fever, sensitization reactions to the ingredients of the product. Do not use if you are allergic to products containing yeast. A similar list of contraindications is inherent in the Bubo M vaccine, which is considered a reliable analogue of the yeast recombinant vaccine.
Featuresapplications
The introduction of a yeast vaccine can cause an increase in overall body temperature. Some people have a headache. The child may feel nauseous. The injection site is sometimes disturbed by pain, it becomes somewhat denser. The product is intended for children and adults. When administered, you must be guided by the national vaccination calendar and instructions for the drug.
The list of recombinant vaccines, in addition to those described, also includes RDNA. This is a recombinant product designed to prevent hepatitis B. In the same list, you can see the pharmaceutical developments Engerix B, Eberbiovak. The product "Euvax B", belonging to the class of prophylactic injections under consideration, is well known.
Regevac B
This product is also recombinant, as stated in the accompanying instructions for use. "Regevak B" is produced in the form of a white liquid, somewhat turning into gray. There should be no visible inclusions. One dose is half a milliliter. It contains 10 µg of virus and buffer ingredients, 25 µg of preservative and aluminum sorbent. The preservative component may be missing. To clarify its presence, you need to study the document accompanying a specific ampoule. Children's dose - 0.5 mg. For adults, twice the volume is set.
Pharmacology
Regevac B is a pharmaceutical product designed to prevent cases of hepatitis B. It contains a specially purified viral antigen. Product maderecombinantly using yeast culture. The vaccine administration program allows the formation of specific antigens in humans. A protective titer is achievable in an average of 90% of vaccine recipients.
The medicine is used when it is necessary to administer vaccine injections according to the national calendar. The drug is indicated for those who come into contact with hepatitis B-infected material, as well as for all he alth workers working with blood. It is necessary to administer the vaccine to people working in the field of manufacturing immunobiological products from human blood.
Cases and practice
Regevac B vaccine manufacturer advises administering this drug to people who are at particular risk of hepatitis B infection. These are people of any age who live in the same house as a carrier of the virus or a person chronically ill with hepatitis. The high-risk category includes residents of orphanages, boarding schools, as well as people who constantly receive blood products, directly blood. The same risks are inherent in patients with a malignant blood disease and those who are forced to endure hemodialysis.
Vaccination is recommended for students enrolled in a medical school of secondary, higher level. This is especially true for graduates. Vaccination is required for those who inject themselves with drugs.
Application features
"Regevak B" is allowed to be administered to a child on the first day, then after a month of life, followed by anothera month later and at the age of one year, if the mother is diagnosed with hepatitis B or such a disease is diagnosed. If a person has not previously received a vaccination, has been in contact with an infected biomaterial, it is necessary to administer the agent first, then a month and two after the first injection.
It is allowed to administer "Regevak B" and drugs prescribed according to the national calendar on the same day. In this case, different syringes are used. Medicines are injected into different parts of the body in need.
